Slides
Page 1
©2026 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated Kidney Program Updates at the American Society of Nephrology Kidney Week 2026 October 23, 2026 Presentation intended for the investment community
Page 2
©2026 Vertex Pharmaceuticals Incorporated 2 Agenda Welcome Susie Lisa, CFA, Senior Vice President, Investor Relations, Vertex Pharmaceuticals Kidney portfolio overview Reshma Kewalramani, M.D., President and Chief Executive Officer, Vertex Pharmaceuticals Inaxaplin in AMKD Akinlolu Ojo, M.D., Ph.D., MBA; Executive Dean of the School of Medicine at the University of Kansas; Professor, Nephrology and Hypertension; Professor, Population Health Povetacicept in IgAN Richard Lafayette, M.D., Professor of Medicine (Nephrology) at the Stanford University Medical Center; Founder and Director of the Stanford Glomerular Disease Center Q&A Session Dr. Kewalramani, Dr. Ojo, Dr. Lafayette
Page 3
©2025 Vertex Pharmaceuticals Incorporated©2026 Vertex Pharmaceuticals Incorporated 3 Safe harbor statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Vertex's expectations for its renal programs, including expectations that the company's four renal programs have first-in-class and/or best-in-class potential, beliefs regarding the commercial potential for the company's renal programs, beliefs regarding the expected patient populations for the company's renal programs, expectations to have four potential kidney launches by 2030, anticipated clinical benefits of inaxaplin, povetacicept and VX-407, expectations regarding the November 30 PDUFA date for povetacicept in IgAN, and expectations for the availability of interim analysis data in the AMKD AMPLITUDE study in early 2027. While Vertex believes the forward-looking statements contained in this presentation are accurate, these forward-looking statements represent the company's beliefs only as of the date of this presentation and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's pipeline programs may notbe available and/or support registration or further development of its potential medicines due to safety, efficacy or other reasons, that the company may be unable to successfully commercialize its renal programs, and other risks listed under “Risk Factors” in Vertex's annual report filed with the Securities and Exchange Commission (SEC) and available through the company's website at www.vrtx.com and on the SEC’s website at www.sec.gov. You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this presentation as new information becomes available.